Applying the WHO global targets for diabetes mellitus

Competing interests

A.Y.Y.C. has received honoraria for speaking and/or consulting from Abbott, Astra Zeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eisai, Eli Lilly, GSK, Insulet, HLS Therapeutics, Janssen, Medtronic, Novo Nordisk, Pfizer, Sanofi and Takeda. A.Y.Y.C. has participated in clinical trials with Applied Therapeutics and Sanofi. S.K. has received speaker fees from Boehringer Ingelheim, Eli Lilly, NovoNordisk, Pfizer and Sanofi. A.-P.K. is employed by the South Africa Medical Research Council (SAMRC). A.-P.K. received funding for research from SAMRC, US National Institutes of Health, UK Medical Research Council and the European and Developing Countries Clinical Trials Partnership (EDCTP). A.-P.K. has received honoraria from Servier Laboratories. A.-P.K. Is a member of the WHO Strategic Advisory Group on non-communicable diseases. C.M. serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz and Vertex. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for C.M. from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics. C.M. serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca and Novartis. Financial compensation for these activities has been received by KU Leuven. C.M. is senior vice president of the European Association for the Study of Diabetes (EASD), chair of the board of the European Diabetes Forum (EUDF), chair of the board of INNODIA iVZW, chair of the board of Hippo and Friends iVZW. J.E.S. has received honoraria for speaking and/or consulting from Zuellig Pharma, Astra Zeneca, Sanofi, Novo Nordisk, MSD, Eli Lilly, Abbott, Mylan, Boehringer Ingelheim and Roche. M.B.G. declares no competing interests.

留言 (0)

沒有登入
gif